Innovation and Global Clinical Trial Participation Are the Focus of CenterWatch’s Latest Special Report on China’s Drug Development Industry
Friday, October 2, 2009
Clinical trials offices (CTOs) have sprung up in academic health centers across the country, but the roles these offices serve vary widely from center to center, according to a new report.
According to an Orange Paper released by Russia-based CRO, Synergy Research Group, Russia’s health agency, the Federal Service on Surveillance in Healthcare and Social Development (RosZdraNadzor, RZN) approved only 129 new clinical trials, including local and bioequivalence studies, during Q2 2009, representing a 17% decrease from Q2 last year. The percentage of approved multinational clinical trials increased slightly, however, to 65% of the total during this time period.
Serbia celebrated International Day of Clinical Trials, which was organized by the Section for Clinical Pharmacology (SCP) of the Serbian Medical Association (SMA). Founded in Belgrade in 1872, the Serbian Medical Association is the largest professional association of doctors in Serbia, who, through their sections, work on development of the medical profession and science in Serbia. The celebration was attended by physicians in all specialties, representatives of Serbian hospitals, contract research organizations (CROs) working in Serbia, sponsor representatives, as well as the management of the Serbian Medical Association.
Working at the Global Level in China
A new report released last week by the Association of Clinical Research Organizations (ACRO) says clinical trials conducted in the developing world not only match the quality and safety standards of those conducted in the developed world but they also improve the global drug development process.